These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Heparin-mediated extracorporeal low-density lipoprotein precipitation: rationale for a specific adjuvant therapy in cardiovascular disease. Blessing F; Wang Y; Walli AK; Seidel D Transfus Apher Sci; 2004 Jun; 30(3):255-66. PubMed ID: 15172631 [TBL] [Abstract][Full Text] [Related]
5. Ig-Therasorb immunoadsorption for selective removal of human immunoglobulins in diseases associated with pathogenic antibodies of all classes and IgG subclasses, immune complexes, and fragments of immunoglobulins. Koll RA Ther Apher; 1998 May; 2(2):147-52. PubMed ID: 10225717 [TBL] [Abstract][Full Text] [Related]
6. Technical and clinical experience with protein A immunoadsorption columns. Belàk M; Borberg H; Jimenez C; Oette K Transfus Sci; 1994 Dec; 15(4):419-22. PubMed ID: 10155559 [TBL] [Abstract][Full Text] [Related]
8. Therapeutic apheresis: where we've been and where we are going. Vogler WR Prog Clin Biol Res; 1982; 106():1-13. PubMed ID: 6757935 [TBL] [Abstract][Full Text] [Related]
10. Treatment of hyperlipidemia with a modified low density lipoprotein apheresis system with dextran sulfate. Zhao YH; Zou YG; Sun QJ; Xi D; Xing CY Ther Apher Dial; 2007 Aug; 11(4):249-54. PubMed ID: 17661829 [TBL] [Abstract][Full Text] [Related]
12. Intravenous immunoglobulin application following immunoadsorption: benefit or risk in patients with autoimmune diseases? Schmaldienst S; Müllner M; Goldammer A; Spitzauer S; Banyai S; Hörl WH; Derfler K Rheumatology (Oxford); 2001 May; 40(5):513-21. PubMed ID: 11371659 [TBL] [Abstract][Full Text] [Related]
13. Immunoadsorption with regenerating systems in neurological disorders --A single center experience. Hohenstein B; Passauer J; Ziemssen T; Julius U Atheroscler Suppl; 2015 May; 18():119-23. PubMed ID: 25936315 [TBL] [Abstract][Full Text] [Related]
14. [Plasma- and lymphapheresis in autoimmune diseases]. Schneider M Z Rheumatol; 1996; 55(2):90-104. PubMed ID: 8686387 [TBL] [Abstract][Full Text] [Related]
16. Neurologic diseases of the central nervous system with pathophysiologically relevant autoantibodies--perspectives for immunoadsorption. Klingel R; Heibges A; Fassbender C Atheroscler Suppl; 2013 Jan; 14(1):161-5. PubMed ID: 23357159 [TBL] [Abstract][Full Text] [Related]
17. Therapeutic immunoadsorption--its role in clinical practice. Braun N; Kadar JG; Risler T Transfus Sci; 1998 Mar; 19 Suppl():65-9. PubMed ID: 10178698 [TBL] [Abstract][Full Text] [Related]
18. Plasmapheresis and immunoadsorption: different techniques and their current role in medical therapy. Schneider KM Kidney Int Suppl; 1998 Feb; 64():S61-5. PubMed ID: 9475492 [TBL] [Abstract][Full Text] [Related]
19. Humoral immune response following extracorporeal immunoadsorption therapy of patients with hypercholesterolemia. Gordon BR; Sloan BJ; Parker TS; Saal SD; Levine DM; Rubin AL Transfusion; 1990 May; 30(4):327-32. PubMed ID: 2190366 [TBL] [Abstract][Full Text] [Related]
20. Quo vadis haemapheresis. Current developments in haemapheresis. Borberg H Transfus Apher Sci; 2006 Feb; 34(1):51-73. PubMed ID: 16412691 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]